ArticleJACC. Case reports2026
Long-Term Heart Failure Stabilization and Autonomic Trends After Bilateral Cardiac Sympathetic Denervation.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBilateral cardiac sympathetic denervation (CSD) is used for refractory ventricular tachycardia (VT); however, its effects on heart failure (HF) progression and left ventricular (LV) remodeling are unclear. CASE SUMMARY: A 64-year-old man with ischemic cardiomyopathy was admitted for refractory monomorphic VT after 4 HF-related hospitalizations in the preceding year. Bilateral CSD for refractory VT eliminated HF-related hospitalizations for 32 months and was associated with LV reverse remodeling, with improved ejection fraction (20% → 30%) and reduced LV end-systolic volume index (66 → 50 mL/m DISCUSSION: CSD exerted a time-limited stabilizing effect on HF and VT. TAKE-HOME MESSAGE: CSD may suppress HF progression and promote LV reverse remodeling. Implantable cardioverter-defibrillator-derived autonomic trends may indicate waning benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.